Sequential deferasirox–deferiprone vs deferasirox or deferiprone alone in beta-thalassemia major

Phase 3, randomised trial in beta thalassemia comparing Deferasirox monotherapy, Deferiprone monotherapy and Sequential deferasirox–deferiprone (3 arms). Primary endpoints: Chelating efficacy of sequential deferasirox–deferiprone vs monotherapy and Renal safety endpoint (creatinine increase). Started Jul 2009; status: terminated.